A decontamination process adding a tensioactive agent and isopropanol to a closed-system drug transfer device for better control of isolator contamination. A prospective, parallel study

Michèle Vasseur1,2, Nicolas Simon1,2*, Chloé Picher3,4, Camille Richeval3,4, Marion Soichot5, Luc Humbert3,4, Christine Barthélémy1, Sandrine Fleury-Souverain6, Pascal Bonnabry6, Bertrand Decaudin1,2, Delphine Allorge3,4, Pascal Odou1,2

1 Univ. Lille, EA 7365—GRITA—Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France, 2 CHU Lille, Institut de Pharmacie, Lille, France, 3 Univ. Lille, EA 4483—IMPECS—IMPact de l’Environnement Chimique sur la Santé humaine, Lille, France, 4 CHU Lille, Pôle de Biologie-Pathologie-Génétique, Unité Fonctionnelle de Toxicologie, Lille, France, 5 Laboratoire de Toxicologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 6 Pharmacy, Geneva University Hospitals and School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland

* nicolas.simon@univ-lille.fr

Abstract

Background

Despite the use of closed system drug transfer devices (CSTD), residual contamination from antineoplastic drugs is still detected inside isolators. The aim of this study was to compare the decontamination level obtained using a CSTD + standard cleaning procedure with a CSTD + standard cleaning procedure + specific decontamination procedure.

Methods and findings

A comparative and prospective study was carried out in a newly opened compounding unit. Compounding was performed with a CSTD (BD-Phaseal, Becton-Dickinson). In the Control isolator (C), the cleaning process was completed daily with a standard biocide solution (Anioxyspray®️, Anios, France). In the Intervention isolator (I), weekly decontamination with a homemade admixture of sodium dodecyl sulfate 10−2 M/70% isopropanol (80/20, v/v) was added. Monitoring was performed via a validated LC-MS/MS method. Eight drugs (cyclophosphamide, cytarabine, dacarbazine, fluorouracil, gemcitabine, ifosfamide, irinotecan and methotrexate) were monitored daily over 14 consecutive weeks on three sites inside the isolators: gloves, workbench and window. Results are presented as the odds-ratio (OR) of contamination and as overall decontamination efficiency (EffQ, %). The proportion of EffQ ≥ 90% was assessed by a Fisher’s exact test (p<0.05). Overall contamination rates (CR, %) were significantly different from one isolator to the other (CRC = 25.3% vs. CRl = 10.4%; OR = 0.341; p<0.0001). Overall EffQ values (median; 1st and 3rd quartiles) were higher in the
Conclusion

Adding a decontamination protocol with a tensioactive agent to a CSTD leads to better control of chemical contamination inside isolators. Improving decontamination by increasing decontamination frequency or modifying the protocol will be further studied.

Introduction

The occupational exposure of healthcare workers to antineoplastic drugs was firstly described several decades ago [1]. Despite efforts to combat it, this topic remains an issue for healthcare workers [2]. The risks associated with occupational exposure to antineoplastic drugs can be genotoxic effects or a decrease in reproductive functioning [3,4]. Several sources of contamination have been determined in hospital settings: in pharmacies, notably on the external surface of commercial vials [5], during the compounding process [6], inside isolators [7] and in medical wards (e.g. preparations coming from the pharmacy and patients’ excreta) [8]. Soon after the first observation of this occupational exposure, professional recommendations were published [9]. Since then, they have been amended and improved. It is strongly advised today to wear personal protective equipment and use barrier isolators or laminar airflow hoods [10,11]. A regular update in healthcare workers’ training is also recommended [10,11].

In a compounding area, contamination may be translocated through direct contact with the contaminated surfaces of vials, by leaks or aerosolization or it may simply be spread by hands. Indeed, contamination has been detected on the ground in front of hoods or isolators and even on a computer mouse or phone [12].

It is therefore essential to decrease contamination resulting from the compounding process. In the past ten years, closed-system transfer devices (CSTD) have been promoted in guidelines [11]. These devices are intended to avoid direct contact between the preparation’s surroundings and antineoplastic drugs by “mechanical prohibition of the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system” [13].

Recently, we have demonstrated that using a CSTD (BD-Phaseal, Becton-Dickinson, France) leads to a 50% reduction in the number of samples contaminated by ten cytotoxic drugs when compared to standard compounding devices (needles and mainly spikes) [6]. Although our results showed a significant difference in favor of the CSTD, residual contamination was still observed, as in other studies [14–16]. Furthermore, the efficacy of the CSTD is variable according to the drug tested. Means should therefore be reinforced to decrease contamination inside isolators and so reduce the probability of its spreading to surroundings.

Several studies have been carried out to find the best decontaminating solution [17–19]. It has previously been shown that decontaminating solutions including tensioactive agents could have a significant effect on residual contamination [19]. Tensioactive agents or surfactants are specific chemicals characterized by their structural bipolarity: one hydrophobic group and another hydrophilic group. They are classified as anionic, cationic or non-ionic surfactants and have various uses in healthcare, such as excipients to dissolve hydrophobic drugs in aqueous solutions or to compound injectable emulsions. Their interest in chemical decontamination is...
closely related to their ability to dissolve both hydrophilic and hydrophobic drugs, and then to be wiped on tissues. Queruau-Lamerie et al. established that solutions containing an admixture of anionic surfactant and isopropyl alcohol were effective in terms of surface decontamination [20]. These results paved the way for an assessment of a multifactorial approach combining the use of a CSTD with an optimized decontamination process.

The aim of the present study is then to assess the combination of a compounding process using a CSTD and a decontamination procedure including a solution specific to this same compounding process along with a standard cleaning process and to compare with the classic CSTD and standard cleaning procedure.

Materials and methods

Description of the compounding unit

The study was performed in a hospital compounding unit in which 45,000 preparations of cytotoxic drugs were compounded in 2016. The study started on December 16th 2015 and was over on March 23rd 2016. Three hospital pharmacists manage the compounding unit and 8.5 pharmacy technicians are employed in the compounding of antineoplastic drugs. All the pharmacy technicians are experienced personnel with CSTD knowledge and practice. This study took place just after the opening of the new compounding unit.

This unit is equipped with 4 new isolators (IM2111 and 2 IM1222, Sieve, Villeurbanne, France) and a total of 6 workplaces. Only the two IM1222 isolators (one workplace at each) were used in this study. One isolator was the “Control” (C) and the other the “Intervention” (I). The compounding process was performed on a BD-Phaseal (Becton Dickinson, Le Pont de Claix, France) in both isolators.

Study design

Ethics statement. Lille University hospital benefited from a grant for this study. Since this study did not involve either human subjects or animals, no authorization had to be obtained from the ethics committee.

Distribution of compounded drugs inside isolators. Eight frequently prescribed drugs were chosen as contamination markers: cyclophosphamide, cytarabine, dacarbazine, 5-fluorouracile (5FU), gemcitabine, ifosfamide, irinotecan and methotrexate. To avoid any bias in their distribution inside the two isolators, it was decided to switch their compounding from one isolator to the other every day.

All preparations involving the monitored drugs were compounded with BD-Phaseal by specifically trained pharmacy technicians, who have been using this device in routine conditions for more than 1.5 years. So as not to interrupt the compounding activity essential for patients’ treatment, the other drugs were distributed among the four remaining workplaces.

The pharmacy technicians were assigned to one or the other workplace according to work organization in the unit.

Recording of critical incidents. To avoid bias in the study, any critical incident that could lead to chemical contamination was recorded. A critical incident was defined as vial breakage, spill or leak of drug inside either of the isolators.

Cleaning and decontamination procedures. The cleaning procedure inside isolators consisted of a daily cleaning process as well as a complete cleaning procedure followed by surface sterilization every 14 days. The daily cleaning procedure was performed at the same time each day in both isolators using a classic biocide (Anioxyspray™, Anios, Lille, France), composed of ethanol (91.6 mg/g) and hydrogen peroxide (50 mg/g). This procedure was always
performed after the morning compounding phase, corresponding to 80–90% of the daily production.

The fortnightly procedure involved a thorough cleaning of the whole isolator including the storage boxes inside the isolator with Anioxyspray\textsuperscript{TM} (Anios, Lille, France) followed by 90 mins’ exposure to vaporized H\textsubscript{2}O\textsubscript{2}. Neoprene gloves were changed on sterilization days unless a barrier disruption had occurred between two sterilization days.

Although the standard daily microbicide cleaning was the only cleaning procedure to remove both bacterial and chemical contamination in the two isolators, there was a difference from one isolator to the other in that a specific weekly decontamination process was added to the “intervention group” aimed at removing chemical contamination and adapted from Anastasi et al.’s research [21]. This protocol was implemented on Wednesdays, this being the day with the lowest compounding activity in the week. A solution mixture containing 80% of an aqueous solution of sodium dodecylsulfate (SDS) at $10^{-2}$ M and 20% of an aqueous solution of 70% isopropanol (IPA) was used [21]. After this decontamination process, the isolator was rinsed with water for injection to remove all potential residue and finally cleaned with classic biocide. The decontamination solution was prepared by the pharmacy each month under a laminar air-flow hood, conditioned in a sterile spray-bottle and tested to be bacteria-free before use, according to the European Pharmacopeia monograph 2.6.1 [22].

The decontamination procedures were performed by a pharmacy technician or by a pharmacist.

**Contamination assessment.** Both isolators were sampled on each working day over 14 consecutive weeks. The eight drugs were monitored in each isolator.

The assay used was the same as that described in a previous study which compared the contamination of isolators after using standard or BD-Phaseal devices [6]. Sampling was carried out daily with 100 μl water for injection and 5x5 cm compresses (ref. 22104KL1, Tetramedical, Annonay, France) inside the isolators. Three sites were defined at each workplace: worktop, inside face of window and gloves. Samples were taken on 10x10 cm surfaces (worktop and window) and on the whole gloves. This took place before and after the daily cleaning/decontamination procedure after preparing blank samples by filling a tube with a compress inside the isolator but without wiping. Samples were immediately frozen (-20°C) and analyzed within the following 14 days because of the instability of certain drugs (Nussbaumer et al., [23]).

Drugs were extracted from wipes with 2 mL of 0.1% formic acid in methanol over 20 minutes after placing 75 μL internal standard (clonazepam) solution on compresses. Samples were then centrifuged (4500 rpm for 10 min). After retrieving the wipes, solvent was evaporated at 40°C under nitrogen stream. The dry residual was dissolved with 100 μL 0.2% formic acid in acetonitrile.

The concentration was measured by liquid chromatography coupled to a tandem mass spectrometer (Xevo TQ-S, Waters, Guyancourt, France). Briefly, the analytes were separated over 4 minutes on a stationary phase Acquity UPLC C\textsubscript{18} (1.8 μm, 2.1x150 mm) with an injection volume of 7.5 μL. The gradient mobile phase was composed of 5 mM ammonium formate buffer, 0.1% formic acid in water/0.1% formic acid in acetonitrile. The method was validated according to the technical guidelines provided by the French National Accreditation organization (COFRAC) for method validation in medical biology [24]. The lower limit of quantification (LOQ) was 1 ng (per analyzed surface) for cyclophosphamide, gemcitabine, ifosfamide and 10 ng for cytarabine, dacarbazine, fluorouracil, irinotecan and methotrexate. The limit of detection (LOD) was 1 ng for all drugs.

**Outcomes and statistics.** The primary outcome was the contamination rate (CR, %) inside isolators after decontamination. A sample was considered contaminated if at least one drug was detected after analysis. No contamination was recorded if the drug amount was less than 1 ng.
CR corresponds to the division of the number of samples with a detectable amount of drugs (> LOD) divided by the total number of measured samples. The study was designed to highlight a 50% difference in CR between the two isolators by using the following formula:

\[ n = \frac{1}{2} \times \left( \frac{z_{\alpha/2} - z_{1-\beta}}{\sin\sqrt{P_1} - \sin\sqrt{P_2}} \right)^2 \]  

(1)

\[ z_{\alpha/2} \] corresponds to type I risk and was fixed at 0.05, in a bilateral position;
\[ z_{1-\beta} \] corresponds to type II risk and was fixed at 0.85;
P1 corresponds to the first proportion and was fixed at 12.2%, respecting the literature [6] and P2 was estimated at 6.1%. The target number of analyses to be computed was 780.

For any sample with contamination above the lower limit of quantification for the assay, contamination is expressed in ng. Contamination was assessed by the minimum, median, maximum and also the 1st and 3rd quartile values.

The secondary outcome was the decontamination efficacy of the studied solutions. Decontamination efficiency was computed for each drug (Effq) or for all drugs (EffQ) according to Anastasi et al., using the following formula:

\[ \text{Eff}_q = 1 - \frac{\text{sum of contamination after cleaning (ng)}}{\text{sum of contamination before cleaning (ng)}} \]  

(2)

In the case of a higher contamination value after decontamination, negative values of Effq were replaced by 0%. As no toxicological reference values are currently available, our target for overall contamination was the lowest obtainable. In our institution, we therefore considered reasonable an EffQ value of at least 90%.

The study was performed under blind conditions. Results were communicated by the toxicology laboratory after the final sampling.

Statistics were established from the two isolators (Control vs. Intervention). Continuous data (e.g. handled doses) were compared by a Student’s t-test or a Mann-Whitney test. Categorical data (e.g. contamination rates) were compared by a Chi\(^2\) test or a Fisher exact test. All tests had a significance level of 5%.

**Results**

**Study description**

2,776 preparations containing the monitored drugs were compounded over 68 consecutive days. The number of preparations compounded was similar for the two isolators (1,417 in the Control isolator vs. 1,359 in the Intervention isolator) (Table 1). The delay (m±sd) between sampling and dosing days was compatible with drug stability [23]: 7.0±3.8 days with a maximum delay of 14 days for two sampling batches. A total of 1,088 samples were collected, including 272 blanks. The number of study samples was therefore 816. There was no significant difference in the mean compounded doses between the two isolators (Table 1). No critical incident occurred in either isolator during the study.

**Assessment of isolator contamination by antineoplastic drugs**

**Contamination analysis.** Initial contamination was determined before the compounding unit opened and was confirmed to be null. Contamination levels for both isolators during the study are summarized in Table 2.
During the study, contamination rates for blanks were 1.1% in the Control isolator and 0.8% in the Intervention isolator (p = 1.00). Overall contamination rates after the daily cleaning/decontamination process were significantly different for each group (CR\textsubscript{C} = 25.3% vs. CR\textsubscript{I} = 10.4%; Odds-Ratio = 0.341; p < 0.0001).

As regards the surfaces tested, contamination rates were always significantly lower in the Intervention isolator after the cleaning process (Table 3). Contamination rates were different according to the surface tested: e.g. gloves were more contaminated than worktop or inside face of window.

Fig 1. indicates the CR for each drug in each group before and after the cleaning/decontamination process for each studied surface. Cyclophosphamide, ifosfamide, cytarabine, and gemcitabine had a lower CR after the cleaning process in the Intervention group on gloves. For the worktop, a decrease in CR is observed for gemcitabine after the decontamination process. On the window, the lowest CR is observed in the Intervention group after the decontamination process for all drugs except gemcitabine. The decontamination process had no particular effect on 5-FU contamination. Dacarbazine and methotrexate were never detected in the study.

Contamination amount generally appears to be lower after the decontamination process for each surface studied in the Intervention isolator compared to those in the Control isolator (Tables 4–6).

**Analysis of decontamination efficiency.** A comparison of Eff\textsubscript{Q} values for all study days (N = 68) with a non-parametric Mann and Whitney test results in a significant difference: the medians and [1\textsuperscript{st} and 3\textsuperscript{rd} quartiles] were 59.5% [-5.5%;72.6%] and 78.3% [34.6%;92.6%] for Control and Intervention groups, respectively (p = 0.0015). If there was no difference in the number of sampling days with Eff\textsubscript{Q} ≤ 0% (Control: 19 vs. Intervention: 10; p = 0.096), a significant difference was observed for the number of sampling days with Eff\textsubscript{Q} ≥ 90% (Control: 6 vs.

Table 1. Distribution of compounded doses (in mg) and number of preparations (N) in the two isolators. Results are given as mean±standard deviation.

|          | Control    | Intervention | P   |
|----------|------------|--------------|-----|
| Dose     | N          | Dose         | N   |
| 5-fluorouracil | 2521±1728 | 504 | 2492±1730 | 446 | 0.796 |
| Cyclophosphamide | 1138±786 | 235 | 1151±793 | 209 | 0.868 |
| Cytarabine   | 1524±1946 | 272 | 1470±2018 | 267 | 0.751 |
| Dacarbazine | 593.6±108.5 | 30 | 595.4±122.7 | 24 | 0.956 |
| Gemcitabine | 1712±329 | 159 | 1684±331 | 169 | 0.440 |
| Ifosfamide   | 2842±2289 | 29 | 2105±1080 | 20 | 0.139 |
| Irinotecan   | 295.4±61.4 | 124 | 286.59±64.05 | 169 | 0.235 |
| Methotrexate | 3015±2471 | 64 | 3358±2478 | 55 | 0.453 |

https://doi.org/10.1371/journal.pone.0201335.t001

|                  | Control | Intervention |
|------------------|---------|--------------|
|                  | Before cleaning | After cleaning | Before cleaning | After cleaning |
|                  | Min     | Q1           | Median       | Q3       |
| Min              | 3.7     | 82.3         | 206.6        | 717.8    |
| Q1               | 3.6     | 39.8         | 142.7        | 283.5    |
| Median           | 0.0     | 42.4         | 130.7        | 285.3    |
| Q3               | 0.0     | 3.1          | 31.7         | 102.1    |
| Max              | 11589   | 1848         | 2625         | 1627     |

https://doi.org/10.1371/journal.pone.0201335.t002
Intervention: 21; p = 0.0005), or Eff\(\text{Q}\) = 100% (Control: 0 vs. Intervention: 11; p = 0.0002).

Decontamination efficiency (Eff\(\text{Q}\)) was different depending on the drug analyzed. The values of Eff\(\text{Q}\) for 5FU, cytarabine, ifosfamide, cyclophosphamide and gemcitabine are reported in Table 7. In the case of irinotecan, more contamination was measured in the Control group after cleaning (mean: 64.0 ng; 6 days) than before (mean: 43.0 ng; 2 days) whereas in the Intervention group, contamination was lower after cleaning (26.6 ng; 2 days) than before (331.0 ng; 1 day).

When focusing on decontamination days, the mean overall Eff\(\text{Q}\) value was much higher in the Intervention isolator (I: 61.0 ± 41.5% vs. C: 42.4 ± 37.3%; p = 0.136), but very variable depending on drugs. Decontamination was more effective for both cyclophosphamide and gemcitabine. The proportion of days with an Eff\(\text{Q}\) ≥ 90% was higher in the Intervention isolator (I: 42.9% vs. C: 7.1%; p = 0.077). Therefore, residual contamination remained (median: 19 ng).

Decontamination efficiency was also variable according to the tested surface (Tables 4–6). In the Control isolator, the highest decontaminating effect was observed for irinotecan on gloves and for gemcitabine on both worktop and window, whereas the lowest effect was observed for gemcitabine on gloves, for cyclophosphamide on worktop and for cytarabine on window. In the Intervention isolator, the highest decontaminating effect was noted for ifosfamide on gloves and for irinotecan on both worktop and window, whereas the lowest was to be found for cyclophosphamide on gloves, for 5FU on worktop and for gemcitabine on window.

### Discussion

Various means have to be combined to ensure maximum control of chemical contamination by antineoplastic drugs inside isolators. Three main sources of contamination have been identified: the outside surface of vials, the compounding process (leakage and aerosolization) and spreading by contaminated hands. The results of the present study show a significant difference between the two strategies tested. Indeed, the combination of a CSTD + daily cleaning + weekly decontamination process led to a significant reduction in isolator contamination compared to the association of a CSTD + daily cleaning only, especially for cyclophosphamide, ifosfamide, cytarabine and gemcitabine.

Contamination evolution was very variable throughout the study in both isolators, but showed a decreasing trend over time. Contamination measured after cleaning/decontamination was generally lower than contamination measured before, although sometimes it could be higher. This phenomenon has already been reported elsewhere [21]. If there is no logical explanation, it may be hypothesized that the cleaning process is sometimes involved in spreading.
Adding a specific decontamination process to a CSTD to reduce surface contamination of isolators
contamination rather than desorbing drugs. Nevertheless, contamination was shown to be globally lower in the Intervention isolator, both for the decontamination days and for the periods between two decontamination days. The use of a specific cleaning solution helped to reduce the occurrence of inefficiency (Eff\(Q\leq 0\%\)) and significantly increased the number of days with high Eff\(Q\) (Eff\(Q\geq 90\%\)).

Overall CR before cleaning was observed to be much lower in the Intervention group. As CR reflects the cumulative effect of residual contamination after cleaning/decontamination and contamination generated during compounding, it is likely that the CR observed in the Intervention isolator is a consequence of the decontamination process and the compounding. As the compounding underwent no modifications (same drug vials, same pharmacy technicians . . .), it can be asserted that the CR was due to decontamination.

The study was performed inside isolators regularly sterilized by vaporized H\(_2\)O\(_2\). If regular sterilization is always programmed, impromptu sterilization may be required in the case of sterility disruption. No specific effect on contamination was expected, as already indicated in a previous publication [25].

When focusing on the contamination rates observed on decontamination days, contamination was significantly lower in the Intervention isolator over the whole study period. However, the difference was not always significant, showing how dynamic contamination evolution is in relation to time, as demonstrated earlier by Anastasi et al. [21].

The difference observed was also dependent on the tested drug and surface. Even if slight differences were observed in decontamination efficacy between this study and that of Queruau-Lamerie et al., decontamination efficacy levels are close to those previously obtained during simulated contamination studies [20], except for cytarabine whose decontamination efficacy was significantly lower in this study. This difference could be due to several factors, such as the difference in contamination amount, surface type or wipes used.

The analytical assay used for contamination measurement was the same as the one used in a previous study [6]. Although blank samples were not contaminated before the study began, a

---

Table 4. Contamination values on decontamination days and decontamination efficiency (in %) on gloves. Contamination values (in ng) correspond to the sum of contamination measured before or after the cleaning/decontamination process.

| Day | Control Before | After | Eff\(Q\) | Intervention Before | After | Eff\(Q\) |
|-----|----------------|-------|----------|---------------------|-------|----------|
| 6   | 127.86         | 27.99 | 78%      | 2.76                | 0.00  | 100%     |
| 10  | 94.04          | 69.85 | 26%      | 51.29               | 0.00  | 100%     |
| 14  | 60.75          | 18.98 | 69%      | 180.43              | 0.00  | 100%     |
| 19  | 57.81          | 2.03  | 96%      | 99.09               | 41.21 | 58%      |
| 24  | 693.26         | 440.89| 36%      | 0.00                | 0.00  | -        |
| 29  | 201.13         | 14.61 | 93%      | 16.25               | 16.78 | 0%       |
| 34  | 37.51          | 1.43  | 96%      | 3.51                | 0.00  | 100%     |
| 38  | 416.70         | 172.56| 59%      | 24.29               | 69.41 | 0%       |
| 43  | 68.25          | 560.80| 0%       | 43.69               | 21.35 | 51%      |
| 48  | 273.32         | 304.04| 0%       | 72.07               | 0.00  | 100%     |
| 53  | 0.00           | 0.00  | -        | 149.27              | 0.00  | 100%     |
| 58  | 138.75         | 29.85 | 78%      | 150.89              | 26.75 | 82%      |
| 63  | 649.94         | 19.49 | 97%      | 107.40              | 0.00  | 100%     |
| 68  | 59.87          | 44.38 | 26%      | 334.61              | 386.94| 0%       |

https://doi.org/10.1371/journal.pone.0201335.t004
few blank samples became contaminated during the study, probably due to handling errors during sampling. As shown in our results, the contamination rates of blank samples were very low and no difference was evident between the two isolators. There was therefore a reduction in the number of contaminated samples in the Intervention isolator, leading to the conclusion that the addition of a weekly decontamination process may provide better control of residual contamination inside isolators than simply the use of a CSTD and daily cleaning with a microbicide solution. This study also shows that standard biocide solutions are not effective in removing chemical contamination. In our previous study which aimed at assessing the effect of implementing a CSTD in the compounding process when standard biocide is used as decontaminating agent, the sum of contamination observed

Table 5. Contamination values on decontamination days and decontamination efficiency (in %) on worktop. Contamination values (in ng) correspond to the sum of contamination measured before or after the cleaning/decontamination process.

| Day | Control Before | Control After | Efficiency | Intervention Before | Intervention After | Efficiency |
|-----|----------------|---------------|------------|---------------------|-------------------|------------|
| 6   | 37.34          | 109.01        | 0%         | 121.40              | 20.42             | 83%        |
| 10  | 89.01          | 34.40         | 61%        | 0.00                | 14.55             | 0%         |
| 14  | 5.57           | 0.00          | 100%       | 236.06              | 0.00              | 100%       |
| 19  | 78.51          | 0.00          | 100%       | 0.00                | 0.00              | -          |
| 24  | 179.49         | 22.84         | 87%        | 0.00                | 0.00              | -          |
| 29  | 33.12          | 6.50          | 80%        | 0.00                | 0.00              | -          |
| 34  | 10.46          | 0.00          | 100%       | 48.90               | 1.07              | 98%        |
| 38  | 81.52          | 34.90         | 57%        | 0.00                | 0.00              | -          |
| 43  | 15.74          | 0.00          | 100%       | 0.00                | 0.00              | -          |
| 48  | 59.30          | 9.27          | 84%        | 58.86               | 0.00              | 100%       |
| 53  | 5.97           | 0.00          | 100%       | 0.00                | 0.00              | -          |
| 58  | 308.54         | 4.24          | 99%        | 0.00                | 0.00              | -          |
| 63  | 0.00           | 23.86         | -          | 0.00                | 0.00              | -          |
| 68  | 12.11          | 1198.35       | 0%         | 0.00                | 76.86             | -          |

https://doi.org/10.1371/journal.pone.0201335.t005

Adding a specific decontamination process to a CSTD to reduce surface contamination of isolators

Table 6. Contamination values on decontamination days and decontamination efficiency (in %) on window. Contamination values (in ng) correspond to the sum of contamination measured before or after the cleaning/decontamination process.

| Day | Control Before | Control After | Efficiency | Intervention Before | Intervention After | Efficiency |
|-----|----------------|---------------|------------|---------------------|-------------------|------------|
| 6   | 37.34          | 31.66         | 15%        | 224.85              | 13.07             | 83%        |
| 10  | 89.01          | 57.78         | 35%        | 27.60               | 51.20             | 0%         |
| 14  | 5.57           | 1.10          | 80%        | 49.63               | 0.00              | 100%       |
| 19  | 78.51          | 72.88         | 7%         | 0.00                | 0.00              | -          |
| 24  | 179.49         | 1383.88       | 0%         | 12.65               | 0.00              | 100%       |
| 29  | 33.12          | 6.21          | 41%        | 12.99               | 0.00              | 100%       |
| 34  | 10.46          | 62.26         | 24%        | 0.00                | 0.00              | -          |
| 38  | 81.52          | 5.95          | 62%        | 15.47               | 0.00              | 100%       |
| 43  | 59.30          | 83.02         | 0%         | 0.00                | 0.00              | -          |
| 48  | 5.97           | 10.02         | 0%         | 0.00                | 0.00              | -          |
| 53  | 308.54         | 17.74         | 94%        | 12.86               | 0.00              | 100%       |
| 58  | 0.00           | 43.73         | -          | 0.00                | 0.00              | 100%       |
| 63  | 12.11          | 28.67         | -          | 0.00                | 28.67             | -          |

https://doi.org/10.1371/journal.pone.0201335.t006
after cleaning ranged between 17–4400 ng and 0–2250 ng in the groups using standard devices and CSTD, respectively [6]. In the present study, the sum of contamination observed after decontamination/cleaning ranged from 8 to 1850 ng in the Control isolator and 0 to 490 ng in the Intervention isolator. This confirms previously published data.

Efficacy in decontaminating surfaces depends on the decontaminating solution used, and also on the surface to be wiped [17–19,26]. The choice of solution containing SDS and IPA was related to previously published data [17,20] as it proved to be effective on several drugs and several surfaces. In this study, the CR% observed after the cleaning process was reduced by 59% in the Intervention isolator. The OR was 0.341, resulting in a 61.5% reduction in contamination risk. The effect differed depending on the surface: the association of a CSTD + cleaning process + decontamination was better on window > gloves > worktop. This could probably be explained by the fact that wiping is easier on flat surfaces, less exposed to direct contamination (e.g. window) than others, and by the polymer on the surface. On the other hand, the effect was positive on gloves, so decreasing the risk of skin exposure for pharmacy technicians. Moreover, neoprene gloves were changed regularly (every 14 days if no incident) before isolator sterilization.

Considering a target contamination of 10 ng as suggested by the MEWIP project [27], a contamination sum lower than 10 ng after the cleaning process was more frequently observed in the Intervention isolator (data not shown), but it was nevertheless over 10 ng on many study days. These results are consistent with previously published data. The effect of decontamination is variable, which is why, depending on the origin of the contamination (drug type) and on the nature of the surface to be cleaned, the $\text{Eff}_Q$ did not reach 100% on each decontamination day.

In this study, 5FU was identified as being the most contaminating drug in the Intervention isolator after poor decontamination/cleaning efficacy of the SDS solution. Its contamination percentage was 55.8%. Such a result was clearly unexpected considering previously published data [17,18]. In their simulated contamination study, Böhlantdt et al. tested three solutions (i.e. distilled water, $10^{-2}$ M SDS/70 IPA -80/20- and towelettes soaked with propan-1-ol and propan-2-ol) on four surfaces (glass, stainless steel, polyvinyl chloride and laminated wood), different from ours, with 1 ng/cm$^2$ of 5-FU [17]. An $\text{Eff}_Q$ of over 99% was observed on a glass surface with the 3 solutions. $\text{Eff}_Q$ levels of 95–99% were observed on PVC and stainless steel surfaces with the three tested solutions. Whatever the decontaminant used on laminated wood, $\text{Eff}_Q$ was under 95%. In their study, Cox et al. tested a marketed towelette kit soaked with a quaternary ammonium solution and isopropanol on a stainless steel surface to obtain an $\text{Eff}_Q$ of over 98% [18].

Decontamination efficiency depends on the drug (type and amount), the decontaminating solution, the surface type, but also on the analytical technique used to quantify drugs. In the case of 5-FU, which is a very hydrophilic drug, dosing remains difficult with a reverse-phase LC-MS method, because of its low quantitative performances (in terms of precision, recovery.

### Table 7. Overall decontamination efficiency ($\text{Eff}_Q$) between control and intervention groups.

| Drug          | 5FU | Cytarabine | Ifosfamide | Cyclophosphamide | Gemcitabine |
|---------------|-----|------------|------------|------------------|-------------|
| **Control**   | 91% | 71%        | 29%        | 6%               | 88%         |
|               | [69.1; 100] | [16.4; 97] | [2.5; 64]  | [-47.3; 40]      | [30.5; 100] |
| **Intervention** | 100% | 95%        | 90%        | 100%             | 100%        |
|               | [41.3; 100] | [63.2; 100] | [81.7; 96]  | [58.0; 100]      | [77.7; 100] |
| **P-value**   | 0.842 | 0.026      | 0.0007     | 0.0007           | 0.298       |

https://doi.org/10.1371/journal.pone.0201335.t007
and sensitivity). Most samples had detectable, but unquantifiable, 5-FU amounts (results between LOD and LOQ) in both groups, so that no relevant conclusion could be reached. The results observed on decontamination efficiency on decontamination days require specific study to be clearly understood.

**Conclusion**

This study shows that the use of a specific decontamination solution, including a surfactant and an alcoholic solvent, results in decreasing chemical contamination inside isolators, although it cannot eliminate it totally. Further studies are required to gain better control of all sources of contamination, by reinforcing decontamination methods inside isolators.

**Acknowledgments**

The authors thank Becton-Dickinson laboratories for their help in financing the study.

The authors thank Alexandra Tavernier-Sommerville, M.A. (University of Glasgow U.K.), Professeur Agrégée (France) for her assistance in correcting and editing the text.

**Author Contributions**

**Conceptualization:** Michèle Vasseur, Nicolas Simon, Pascal Bonnabry, Bertrand Décaudin, Pascal Odou.

**Data curation:** Michèle Vasseur, Nicolas Simon.

**Formal analysis:** Michèle Vasseur, Nicolas Simon, Chloé Picher, Camille Richeval, Christine Barthélemy, Bertrand Décaudin.

**Funding acquisition:** Nicolas Simon.

**Investigation:** Michèle Vasseur, Chloé Picher.

**Methodology:** Nicolas Simon, Pascal Bonnabry, Delphine Allorge, Pascal Odou.

**Project administration:** Chloé Picher.

**Supervision:** Michèle Vasseur, Nicolas Simon, Camille Richeval.

**Validation:** Nicolas Simon.

**Visualization:** Michèle Vasseur.

**Writing – original draft:** Nicolas Simon, Chloé Picher, Pascal Odou.

**Writing – review & editing:** Michèle Vasseur, Nicolas Simon, Camille Richeval, Marion Soichot, Luc Humbert, Christine Barthélemy, Sandrine Fleury-Souverain, Pascal Bonnabry, Bertrand Décaudin, Delphine Allorge, Pascal Odou.

**References**

1. Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1(8128):1250–1251. PMID: 87722
2. Graeve CU, McGovern PM, Alexander B, Church T, Ryan A, Polovich M. Occupational Exposure to Antineoplastic Agents. Workplace Health Saf 2017; 65:9–20. https://doi.org/10.1177/21650791662660 PMID: 27759694
3. McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med 2010; 52(10):1028–1034. https://doi.org/10.1097/JOM.0b013e3181f73ae6 PMID: 20881619
4. Connor TH, Lawson CC, Polovich M, McDiarmid M. Reproductive health risks associated with the occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med 2014; 56:901–910. https://doi.org/10.1097/JOM.0000000000000249 PMID: 25153300
5. Mason HJ, Morton J, Garff SJ, Iqbal S, Jones K. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003; 47(8):681–685. PMID: 14602675
6. Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study. PLoS One 2016; 11:e0159052 https://doi.org/10.1371/journal.pone.0159052 PMID: 27391697
7. Crauste-Manciet S, Sessink PJ, Ferrari S, Jonier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49:619–628. https://doi.org/10.1093/annhyg/mei045 PMID: 16126757
8. Hedmer M, Tinnerberg H, Axmon A, Jonsson BAG. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008; 81:899–911. https://doi.org/10.1007/s00420-007-0284-y PMID: 18066576
9. Zimmerman PF, Larsen RK, Barkley EW, Gallelli JF. Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 1981; 38(11): 1693–1695. PMID: 7304621
10. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Hosp Pharm 2006; 63:1172–1193.
11. International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007; 13:1–81. https://doi.org/10.1177/1078155207077591 PMID: 17933809
12. Brouwers EE, Huijtema AD, Bakker EN, Douma JW, Schimmel KJM, van Weringen G et al. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. Int Arch Occup Environ Health 2007; 80:689–699. https://doi.org/10.1007/s00420-007-0181-4 PMID: 17377802
13. National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. 2004 www.cdc.gov/niosh/docs/2004-165/default.html
14. Sessink PJM, Tranah J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US Hospital pharmacies following implementation of a Closed-System Drug Transfer Device. Hosp Pharm 2013; 48(3):204–212. https://doi.org/10.1310/hpj4803-204 PMID: 24421463
15. Connor TH, DeBord DG, Pretty JR, Olive MS, Roth TS, Lees PS, et al. Evaluation of antineoplastic drug exposure of healthcare workers at three university-based US cancer centers. J Occup Environ Med 2010; 52 (10):1019–1027. https://doi.org/10.1097/JOM.0b013e3181f72b63 PMID: 20881620
16. Guillemette A, Langlois H, Voisine M, Merger D, Therrien R, Mercier et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. J Oncol Pharm Pract 2014; 20(6):426–432. https://doi.org/10.1177/1078155213517127 PMID: 24395542
17. Böhllandt A, Groeneveld S, Fischer E, Schierl R. Cleaning Efficiencies of Three Cleaning Agents on Four Different Surfaces after Contamination by Gemcitabine and 5-fluorouracil. J Occup Environ Hyg 2016; 12:384–392.
18. Cox J, Speed V, O’Neal S, Hasselwander T, Sherwood C, Eckel SF et al. Development and evaluation of a novel product to remove surface contamination of hazardous drugs. J Occup Pharm Pract 2016; 23:103–115. https://doi.org/10.1177/1078155215621151 PMID: 26673538
19. Minh Mai Lê L, Jolivot PA, Sadou Yaye H, Rieutord A, Bellanger A, Pradeau D et al. Effectiveness of cleaning of workplace cytotoxic surface. Int Arch Occup Environ Health 2013; 86:333–341. https://doi.org/10.1007/s00420-012-0769-1 PMID: 22926087
20. Queruau-Lamerie T, Nussbaumer S, Décaudin B, Fleury-Souverain, Goossens JF, Bonnabry P. Evaluation of decontamination efficacy of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents. Ann Occup Hyg 2013; 57(4):456–469. https://doi.org/10.1093/annhyg/mes087 PMID: 23223271
21. Anastasi M, Rudaz S, Queruau-Lamerie T, Odou P, Bonnabry P, Fleury-Souverain S. Efficacy of Two Cleaning Solutions for the Decontamination of 10 Antineoplastic Compounds in a Hospital Pharmacy Ann Occup Hyg 2015; 59(7):895–908.
22. European Pharmacopoeia. Edition 9.1. Monograph 2.6.1. Sterility. Strasbourg: 2017.
23. Nussbaumer S, Geiser L, Sadeghipour F, Hochstrasser D, Bonnabry P, Veuthey JL et al. Wipe sampling procedure coupled to LC–MS/MS analysis for the simultaneous determination of 10 cytotoxic
drugs on different surfaces. Anal Bioanal Chem 2012; 402(8):2499–2509. https://doi.org/10.1007/s00216-011-5157-2 PMID: 21701850

24. Comité Français d’Accréditation. SH GTA 04 –Guide technique d’accréditation de vérification (portée A) / validation (portée B) des méthodes de biologie médicale, v09/2015. [In French] https://www.cofrac.fr/fr/documentation/index.php?fol_id=63

25. Roberts S, Khammo N, McDonnell G, Sewell GJ. Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations. J Oncol Pharm Pract. 2006; 12: 95–104. https://doi.org/10.1177/1078155206070439 PMID: 16984748

26. Hon CY, Chua PP, Danyluk Q, Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract 2014; 20(3):210–216. https://doi.org/10.1177/1078155213497070 PMID: 23929731

27. Kiffmeyer TK, Tuerk J, Hahn M, Stuetzer H, Hadtstein C, Heinemann A et al. Application and Assessment of a Regular Environmental Monitoring of the Antineoplastic Drug Contamination Level in Pharmacies—The MEWIP Project. Ann Occup Hyg 2013; 57:444–455. https://doi.org/10.1093/annhyg/mes081 PMID: 23125441